V7B.F Assembly Biosciences, Inc.

Healthcare Biotechnology Frankfurt Exchange
19.56 EUR
Close of Nov 12, 2026
17.12 33.50
Market cap
EUR 398M
P/E
22.0x
P/B
1.42x
ROE
-8.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is V7B.F undervalued?

Graham number
Price19.56
Graham value16.61
Premium17.8%

V7B.F trades 17.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Assembly Biosciences, Inc. fundamental analysis

No fundamental analysis for Assembly Biosciences, Inc. yet.

Assembly Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infec…

Full company profile